Nonprofit Expands Access to Life-Saving Tuberculosis Drug in Poorer Countries

Johnson & Johnson has reached an agreement with nonprofit Stop TB Partnership to allow the distribution of a generic version of its tuberculosis drug, bedaquiline, in low- and middle-income countries. This move will significantly expand access to the life-saving drug, which is currently priced out of reach for many communities. The agreement enables the nonprofit to sell generic versions of the drug in 44 countries where Johnson & Johnson's patents are still in effect. This will help lower the cost of the drug and make it more affordable for those in need.